Benzinga

Benzinga

Benzinga

miércoles, septiembre 02

Crescent Biopharma Inc

CBIONASDAQ
Trade with Public
Trade with Public
$17.93
1.338.01%
al cierre: Sep 1, 5:00 PM EST
$17.93
N/A
After hour: 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Crescent Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crescent Biopharma (CBIO).

Price Target Range — 4 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$28Upside to Avg. PT+53.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026WedbushRobert DriscollMaintainedOutperform$27
Jun 1, 2026HC Wainwright & Co.Mitchell S. KapoorDowngradeBuy→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Crescent Biopharma (NASDAQ:CBIO) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.
Benzinga Newsdesk

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

PRO
Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35

Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved